Alyeska Investment Group
TRML

Alyeska Investment Group’s Tourmaline Bio TRML Stock Holding History

Alyeska Investment Group’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-243,744
Closed -$3.9M – 717
2025
Q2 		$3.9M Buy
243,744
+128,691
+112% +$2.08M 0.01% 441
2025
Q1 		$1.75M Hold
115,053
– – 0.01% 420
2024
Q4 		$2.33M Sell
115,053
-75,000
-39% -$1.89M 0.01% 455
2024
Q3 		$4.89M Sell
190,053
-59,947
-24% -$1M 0.02% 357
2024
Q2 		$3.21M Buy
250,000
+175,000
+233% +$2.82M 0.02% 374
2024
Q1 		$1.72M Buy
+75,000
New +$2.64M 0.01% 385
2021
Q3 		– Sell
-5,000
Closed -$735K – 796
2021
Q2 		$735K Buy
+5,000
New +$766K 0.01% 625

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Alyeska Investment Group's TRML Position: Q3 2025 in Review

Alyeska Investment Group sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 243,744 shares — an estimated $3.9M sold.

Alyeska Investment Group first reported a position in TRML in Q2 2021 and held it in 7 quarters. The position peaked at $4.89M in Q3 2024. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

  • Alyeska Investment Group reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 243,744 Tourmaline Bio shares in Q3 2025, an estimated $3.9M.
  • Alyeska Investment Group first reported a position in Tourmaline Bio in Q2 2021 and held it in 7 quarters.
  • Alyeska Investment Group's Tourmaline Bio position peaked at $4.89M in Q3 2024.
  • 134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on Alyeska Investment Group's 13F filing for Q3 2025, filed 17 Nov 2025.